The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
10-year remission rates following rituximab (R) and FND chemotherapy (fludarabine, mitoxantrone, dexamethasone) with interferon (IFN) maintenance in indolent lymphoma: Results of a randomized study.
Loretta J. Nastoupil
No relevant relationships to disclose
Sattva Swarup Neelapu
No relevant relationships to disclose
Felipe Samaniego
No relevant relationships to disclose
Fredrick B. Hagemeister
No relevant relationships to disclose
Jorge Enrique Romaguera
No relevant relationships to disclose
Larry W. Kwak
No relevant relationships to disclose
Michael Wang
No relevant relationships to disclose
Luis Fayad
No relevant relationships to disclose
Michelle A. Fanale
No relevant relationships to disclose
Yasuhiro Oki
No relevant relationships to disclose
Jason R. Westin
No relevant relationships to disclose
Maria Alma Rodriguez
No relevant relationships to disclose
Fernando Cabanillas
No relevant relationships to disclose
Peter McLaughlin
No relevant relationships to disclose
Nathan Hale Fowler
Consultant or Advisory Role - Roche/Genentech
Research Funding - Roche/Genentech